Efficient Targeted Delivery of Bifunctional Circular Aptamer-ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation
© 2023 Wiley-VCH GmbH..
Inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and excessive inflammation is the current task in the prevention and treatment of corona vireus disease 2019 (COVID-19). Here, a dual-function circular aptamer-ASO chimera (circSApt-NASO) is designed to suppress SARS-CoV-2 replication and inflammation. The chemically unmodified circSApt-NASO exhibits high serum stability by artificial cyclization. It is also demonstrated that the SApt binding to spike protein enables the chimera to be efficiently delivered into the host cells expressing ACE2 along with the infection of SARS-CoV-2. Among them, the SApt potently inhibits spike-induced inflammation. The NASO targeting to silence N genes not only display robust anti-N-induced inflammatory activity, but also achieve efficient inhibition of SARS-CoV-2 replication. Overall, benefiting from the high stability of the cyclization, antispike aptamer-dependent, and viral infection-mediate targeted delivery, the circSApt-NASO displays robust potential against authentic SARS-CoV-2 and Omicron, providing a promising specific anti-inflammatory and antiproliferative reagent for therapeutic COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Small (Weinheim an der Bergstrasse, Germany) - 19(2023), 16 vom: 01. Apr., Seite e2207066 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yang, Gang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiproliferation |
|---|
| Anmerkungen: |
Date Completed 20.04.2023 Date Revised 27.04.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/smll.202207066 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351939482 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351939482 | ||
| 003 | DE-627 | ||
| 005 | 20231226052606.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/smll.202207066 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1173.xml |
| 035 | |a (DE-627)NLM351939482 | ||
| 035 | |a (NLM)36683236 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yang, Gang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficient Targeted Delivery of Bifunctional Circular Aptamer-ASO Chimera to Suppress the SARS-CoV-2 Proliferation and Inflammation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2023 | ||
| 500 | |a Date Revised 27.04.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Wiley-VCH GmbH. | ||
| 520 | |a Inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and excessive inflammation is the current task in the prevention and treatment of corona vireus disease 2019 (COVID-19). Here, a dual-function circular aptamer-ASO chimera (circSApt-NASO) is designed to suppress SARS-CoV-2 replication and inflammation. The chemically unmodified circSApt-NASO exhibits high serum stability by artificial cyclization. It is also demonstrated that the SApt binding to spike protein enables the chimera to be efficiently delivered into the host cells expressing ACE2 along with the infection of SARS-CoV-2. Among them, the SApt potently inhibits spike-induced inflammation. The NASO targeting to silence N genes not only display robust anti-N-induced inflammatory activity, but also achieve efficient inhibition of SARS-CoV-2 replication. Overall, benefiting from the high stability of the cyclization, antispike aptamer-dependent, and viral infection-mediate targeted delivery, the circSApt-NASO displays robust potential against authentic SARS-CoV-2 and Omicron, providing a promising specific anti-inflammatory and antiproliferative reagent for therapeutic COVID-19 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antiproliferation | |
| 650 | 4 | |a circular aptamer-ASO chimera | |
| 650 | 4 | |a omicron | |
| 650 | 4 | |a specific anti-inflammation | |
| 650 | 4 | |a targeted delivery | |
| 700 | 1 | |a Zhang, Shengnan |e verfasserin |4 aut | |
| 700 | 1 | |a Song, William |e verfasserin |4 aut | |
| 700 | 1 | |a Bai, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Ling |e verfasserin |4 aut | |
| 700 | 1 | |a Luo, Fatao |e verfasserin |4 aut | |
| 700 | 1 | |a Cheng, Yiran |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Diyue |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Yanqun |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Jiantao |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jincun |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Yongyun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Small (Weinheim an der Bergstrasse, Germany) |d 2005 |g 19(2023), 16 vom: 01. Apr., Seite e2207066 |w (DE-627)NLM167400452 |x 1613-6829 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:16 |g day:01 |g month:04 |g pages:e2207066 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/smll.202207066 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 16 |b 01 |c 04 |h e2207066 | ||